id,target_word,context_string
d000.s000.t000,document,summary european public assessment report epar
d000.s000.t001,summary,document european public assessment report epar
d000.s000.t002,european,document summary public assessment report epar
d000.s000.t003,public,document summary european assessment report epar
d000.s000.t004,assessment,document summary european public report epar
d000.s000.t005,report,document summary european public assessment epar
d000.s001.t000,explain,committee medicinal product human use chmp assess study perform reach recommendation use medicine
d000.s001.t001,committee,explain medicinal product human use chmp assess study perform reach recommendation use medicine
d000.s001.t002,medicinal,explain committee product human use chmp assess study perform reach recommendation use medicine
d000.s001.t003,product,explain committee medicinal human use chmp assess study perform reach recommendation use medicine
d000.s001.t004,human,explain committee medicinal product use chmp assess study perform reach recommendation use medicine
d000.s001.t005,use,explain committee medicinal product human chmp assess study perform reach recommendation use medicine
d000.s001.t006,assess,explain committee medicinal product human use chmp study perform reach recommendation use medicine
d000.s001.t007,study,explain committee medicinal product human use chmp assess perform reach recommendation use medicine
d000.s001.t008,perform,explain committee medicinal product human use chmp assess study reach recommendation use medicine
d000.s001.t009,reach,explain committee medicinal product human use chmp assess study perform recommendation use medicine
d000.s001.t010,recommendation,explain committee medicinal product human use chmp assess study perform reach use medicine
d000.s001.t011,use,explain committee medicinal product human chmp assess study perform reach recommendation use medicine
d000.s001.t012,medicine,explain committee medicinal product human use chmp assess study perform reach recommendation use
d000.s002.t000,need,information medical condition treatment read package leaflet also part epar contact doctor pharmacist
d000.s002.t001,more,need information medical condition treatment read package leaflet also part epar contact doctor pharmacist
d000.s002.t002,information,need medical condition treatment read package leaflet also part epar contact doctor pharmacist
d000.s002.t003,medical,need information condition treatment read package leaflet also part epar contact doctor pharmacist
d000.s002.t004,condition,need information medical treatment read package leaflet also part epar contact doctor pharmacist
d000.s002.t005,treatment,need information medical condition read package leaflet also part epar contact doctor pharmacist
d000.s002.t006,read,need information medical condition treatment package leaflet also part epar contact doctor pharmacist
d000.s002.t007,package,need information medical condition treatment read leaflet also part epar contact doctor pharmacist
d000.s002.t008,leaflet,need information medical condition treatment read package also part epar contact doctor pharmacist
d000.s002.t009,also,need information medical condition treatment read package leaflet part epar contact doctor pharmacist
d000.s002.t010,part,need information medical condition treatment read package leaflet also epar contact doctor pharmacist
d000.s002.t011,contact,need information medical condition treatment read package leaflet also part epar doctor pharmacist
d000.s002.t012,doctor,need information medical condition treatment read package leaflet also part epar contact pharmacist
d000.s002.t013,pharmacist,need information medical condition treatment read package leaflet also part epar contact doctor
d000.s003.t000,want,information basis chmp recommendation read scientific discussion also part epar
d000.s003.t001,more,want information basis chmp recommendation read scientific discussion also part epar
d000.s003.t002,information,want basis chmp recommendation read scientific discussion also part epar
d000.s003.t003,basis,want information chmp recommendation read scientific discussion also part epar
d000.s003.t004,recommendation,want information basis chmp read scientific discussion also part epar
d000.s003.t005,read,want information basis chmp recommendation scientific discussion also part epar
d000.s003.t006,scientific,want information basis chmp recommendation read discussion also part epar
d000.s003.t007,discussion,want information basis chmp recommendation read scientific also part epar
d000.s003.t008,also,want information basis chmp recommendation read scientific discussion part epar
d000.s003.t009,part,want information basis chmp recommendation read scientific discussion also epar
d000.s005.t000,powder,alimta make_up solution infusion drip vein
d000.s005.t001,make_up,alimta powder solution infusion drip vein
d000.s005.t002,solution,alimta powder make_up infusion drip vein
d000.s005.t003,infusion,alimta powder make_up solution drip vein
d000.s005.t004,drip,alimta powder make_up solution infusion vein
d000.s005.t005,vein,alimta powder make_up solution infusion drip
d000.s006.t000,contain,active substance pemetrex
d000.s006.t001,active,contain substance pemetrex
d000.s006.t002,substance,contain active pemetrex
d000.s007.t000,use,alimta
d000.s008.t000,use,alimta treat two type cancer pleural mesothelioma cancer lining lung usually cause exposure asbestos
d000.s008.t001,treat,alimta use two type cancer pleural mesothelioma cancer lining lung usually cause exposure asbestos
d000.s008.t002,type,alimta use treat two cancer pleural mesothelioma cancer lining lung usually cause exposure asbestos
d000.s008.t003,cancer,alimta use treat two type pleural mesothelioma cancer lining lung usually cause exposure asbestos
d000.s008.t004,pleural,alimta use treat two type cancer mesothelioma cancer lining lung usually cause exposure asbestos
d000.s008.t005,mesothelioma,alimta use treat two type cancer pleural cancer lining lung usually cause exposure asbestos
d000.s008.t006,cancer,alimta use treat two type pleural mesothelioma cancer lining lung usually cause exposure asbestos
d000.s008.t007,lining,alimta use treat two type cancer pleural mesothelioma cancer lung usually cause exposure asbestos
d000.s008.t008,lung,alimta use treat two type cancer pleural mesothelioma cancer lining usually cause exposure asbestos
d000.s008.t009,usually,alimta use treat two type cancer pleural mesothelioma cancer lining lung cause exposure asbestos
d000.s008.t010,cause,alimta use treat two type cancer pleural mesothelioma cancer lining lung usually exposure asbestos
d000.s008.t011,exposure,alimta use treat two type cancer pleural mesothelioma cancer lining lung usually cause asbestos
d000.s008.t012,asbestos,alimta use treat two type cancer pleural mesothelioma cancer lining lung usually cause exposure
d000.s009.t000,use,alimta together_with cisplatin another anticancer medicine cancer unresectable cannot remove surgery alone malignant spread likely spread easily part body patient receive chemotherapy medicine cancer advanced metastatic non-small cell lung_cancer affect squamous_cell
d000.s009.t001,together_with,alimta use cisplatin another anticancer medicine cancer unresectable cannot remove surgery alone malignant spread likely spread easily part body patient receive chemotherapy medicine cancer advanced metastatic non-small cell lung_cancer affect squamous_cell
d000.s009.t002,anticancer,alimta use together_with cisplatin another medicine cancer unresectable cannot remove surgery alone malignant spread likely spread easily part body patient receive chemotherapy medicine cancer advanced metastatic non-small cell lung_cancer affect squamous_cell
d000.s009.t003,medicine,alimta use together_with cisplatin another anticancer cancer unresectable cannot remove surgery alone malignant spread likely spread easily part body patient receive chemotherapy medicine cancer advanced metastatic non-small cell lung_cancer affect squamous_cell
d000.s009.t004,cancer,alimta use together_with cisplatin another anticancer medicine unresectable cannot remove surgery alone malignant spread likely spread easily part body patient receive chemotherapy medicine cancer advanced metastatic non-small cell lung_cancer affect squamous_cell
d000.s009.t005,remove,alimta use together_with cisplatin another anticancer medicine cancer unresectable cannot surgery alone malignant spread likely spread easily part body patient receive chemotherapy medicine cancer advanced metastatic non-small cell lung_cancer affect squamous_cell
d000.s009.t006,surgery,alimta use together_with cisplatin another anticancer medicine cancer unresectable cannot remove alone malignant spread likely spread easily part body patient receive chemotherapy medicine cancer advanced metastatic non-small cell lung_cancer affect squamous_cell
d000.s009.t007,alone,alimta use together_with cisplatin another anticancer medicine cancer unresectable cannot remove surgery malignant spread likely spread easily part body patient receive chemotherapy medicine cancer advanced metastatic non-small cell lung_cancer affect squamous_cell
d000.s009.t008,malignant,alimta use together_with cisplatin another anticancer medicine cancer unresectable cannot remove surgery alone spread likely spread easily part body patient receive chemotherapy medicine cancer advanced metastatic non-small cell lung_cancer affect squamous_cell
d000.s009.t009,spread,alimta use together_with cisplatin another anticancer medicine cancer unresectable cannot remove surgery alone malignant likely spread easily part body patient receive chemotherapy medicine cancer advanced metastatic non-small cell lung_cancer affect squamous_cell
d000.s009.t010,likely,alimta use together_with cisplatin another anticancer medicine cancer unresectable cannot remove surgery alone malignant spread spread easily part body patient receive chemotherapy medicine cancer advanced metastatic non-small cell lung_cancer affect squamous_cell
d000.s009.t011,spread,alimta use together_with cisplatin another anticancer medicine cancer unresectable cannot remove surgery alone malignant likely spread easily part body patient receive chemotherapy medicine cancer advanced metastatic non-small cell lung_cancer affect squamous_cell
d000.s009.t012,easily,alimta use together_with cisplatin another anticancer medicine cancer unresectable cannot remove surgery alone malignant spread likely spread part body patient receive chemotherapy medicine cancer advanced metastatic non-small cell lung_cancer affect squamous_cell
d000.s009.t013,other,alimta use together_with cisplatin another anticancer medicine cancer unresectable cannot remove surgery alone malignant spread likely spread easily part body patient receive chemotherapy medicine cancer advanced metastatic non-small cell lung_cancer affect squamous_cell
d000.s009.t014,part,alimta use together_with cisplatin another anticancer medicine cancer unresectable cannot remove surgery alone malignant spread likely spread easily body patient receive chemotherapy medicine cancer advanced metastatic non-small cell lung_cancer affect squamous_cell
d000.s009.t015,body,alimta use together_with cisplatin another anticancer medicine cancer unresectable cannot remove surgery alone malignant spread likely spread easily part patient receive chemotherapy medicine cancer advanced metastatic non-small cell lung_cancer affect squamous_cell
d000.s009.t016,patient,alimta use together_with cisplatin another anticancer medicine cancer unresectable cannot remove surgery alone malignant spread likely spread easily part body receive chemotherapy medicine cancer advanced metastatic non-small cell lung_cancer affect squamous_cell
d000.s009.t017,not,alimta use together_with cisplatin another anticancer medicine cancer unresectable cannot remove surgery alone malignant spread likely spread easily part body patient receive chemotherapy medicine cancer advanced metastatic non-small cell lung_cancer affect squamous_cell
d000.s009.t018,receive,alimta use together_with cisplatin another anticancer medicine cancer unresectable cannot remove surgery alone malignant spread likely spread easily part body patient chemotherapy medicine cancer advanced metastatic non-small cell lung_cancer affect squamous_cell
d000.s009.t019,chemotherapy,alimta use together_with cisplatin another anticancer medicine cancer unresectable cannot remove surgery alone malignant spread likely spread easily part body patient receive medicine cancer advanced metastatic non-small cell lung_cancer affect squamous_cell
d000.s009.t020,medicine,alimta use together_with cisplatin another anticancer cancer unresectable cannot remove surgery alone malignant spread likely spread easily part body patient receive chemotherapy medicine cancer advanced metastatic non-small cell lung_cancer affect squamous_cell
d000.s009.t021,cancer,alimta use together_with cisplatin another anticancer medicine unresectable cannot remove surgery alone malignant spread likely spread easily part body patient receive chemotherapy medicine cancer advanced metastatic non-small cell lung_cancer affect squamous_cell
d000.s009.t022,advanced,alimta use together_with cisplatin another anticancer medicine cancer unresectable cannot remove surgery alone malignant spread likely spread easily part body patient receive chemotherapy medicine cancer metastatic non-small cell lung_cancer affect squamous_cell
d000.s009.t023,metastatic,alimta use together_with cisplatin another anticancer medicine cancer unresectable cannot remove surgery alone malignant spread likely spread easily part body patient receive chemotherapy medicine cancer advanced non-small cell lung_cancer affect squamous_cell
d000.s009.t024,cell,alimta use together_with cisplatin another anticancer medicine cancer unresectable cannot remove surgery alone malignant spread likely spread easily part body patient receive chemotherapy medicine cancer advanced metastatic non-small lung_cancer affect squamous_cell
d000.s009.t025,lung_cancer,alimta use together_with cisplatin another anticancer medicine cancer unresectable cannot remove surgery alone malignant spread likely spread easily part body patient receive chemotherapy medicine cancer advanced metastatic non-small cell affect squamous_cell
d000.s009.t026,not,alimta use together_with cisplatin another anticancer medicine cancer unresectable cannot remove surgery alone malignant spread likely spread easily part body patient receive chemotherapy medicine cancer advanced metastatic non-small cell lung_cancer affect squamous_cell
d000.s009.t027,affect,alimta use together_with cisplatin another anticancer medicine cancer unresectable cannot remove surgery alone malignant spread likely spread easily part body patient receive chemotherapy medicine cancer advanced metastatic non-small cell lung_cancer squamous_cell
d000.s009.t028,squamous_cell,alimta use together_with cisplatin another anticancer medicine cancer unresectable cannot remove surgery alone malignant spread likely spread easily part body patient receive chemotherapy medicine cancer advanced metastatic non-small cell lung_cancer affect
d000.s010.t000,use,alimta combination cisplatin patient treat patient receive another type chemotherapy past
d000.s010.t001,combination,alimta use cisplatin patient treat patient receive another type chemotherapy past
d000.s010.t002,patient,alimta use combination cisplatin treat patient receive another type chemotherapy past
d000.s010.t003,not,alimta use combination cisplatin patient treat patient receive another type chemotherapy past
d000.s010.t004,treat,alimta use combination cisplatin patient patient receive another type chemotherapy past
d000.s010.t005,patient,alimta use combination cisplatin treat patient receive another type chemotherapy past
d000.s010.t006,receive,alimta use combination cisplatin patient treat patient another type chemotherapy past
d000.s010.t007,type,alimta use combination cisplatin patient treat patient receive another chemotherapy past
d000.s010.t008,chemotherapy,alimta use combination cisplatin patient treat patient receive another type past
d000.s010.t009,past,alimta use combination cisplatin patient treat patient receive another type chemotherapy
d000.s011.t000,medicine,obtain prescription
d000.s011.t001,only,medicine obtain prescription
d000.s011.t002,obtain,medicine prescription
d000.s011.t003,prescription,medicine obtain
d000.s012.t000,use,alimta
d000.s013.t000,only,alimta give supervision doctor qualify use anticancer chemotherapy
d000.s013.t001,give,alimta supervision doctor qualify use anticancer chemotherapy
d000.s013.t002,supervision,alimta give doctor qualify use anticancer chemotherapy
d000.s013.t003,doctor,alimta give supervision qualify use anticancer chemotherapy
d000.s013.t004,use,alimta give supervision doctor qualify anticancer chemotherapy
d000.s013.t005,anticancer,alimta give supervision doctor qualify use chemotherapy
d000.s013.t006,chemotherapy,alimta give supervision doctor qualify use anticancer
d000.s014.t000,dose,recommend alimta mg per square_metre body surface_area calculate use patient height weight
d000.s014.t001,mg,recommend dose alimta per square_metre body surface_area calculate use patient height weight
d000.s014.t002,square_metre,recommend dose alimta mg per body surface_area calculate use patient height weight
d000.s014.t003,body,recommend dose alimta mg per square_metre surface_area calculate use patient height weight
d000.s014.t004,surface_area,recommend dose alimta mg per square_metre body calculate use patient height weight
d000.s014.t005,calculate,recommend dose alimta mg per square_metre body surface_area use patient height weight
d000.s014.t006,use,recommend dose alimta mg per square_metre body surface_area calculate patient height weight
d000.s014.t007,patient,recommend dose alimta mg per square_metre body surface_area calculate use height weight
d000.s014.t008,height,recommend dose alimta mg per square_metre body surface_area calculate use patient weight
d000.s014.t009,weight,recommend dose alimta mg per square_metre body surface_area calculate use patient height
d000.s015.t000,give,every three week intravenous infusion last minute
d000.s015.t001,once,give every three week intravenous infusion last minute
d000.s015.t002,every,give three week intravenous infusion last minute
d000.s015.t003,week,give every three intravenous infusion last minute
d000.s015.t004,intravenous,give every three week infusion last minute
d000.s015.t005,infusion,give every three week intravenous last minute
d000.s015.t006,last,give every three week intravenous infusion minute
d000.s015.t007,minute,give every three week intravenous infusion last
d000.s016.t000,reduce,side_effect patient take corticosteroid folic_acid type vitamin receive injection vitamin_b12 treatment alimta
d000.s016.t001,side_effect,reduce patient take corticosteroid folic_acid type vitamin receive injection vitamin_b12 treatment alimta
d000.s016.t002,patient,reduce side_effect take corticosteroid folic_acid type vitamin receive injection vitamin_b12 treatment alimta
d000.s016.t003,take,reduce side_effect patient corticosteroid folic_acid type vitamin receive injection vitamin_b12 treatment alimta
d000.s016.t004,corticosteroid,reduce side_effect patient take folic_acid type vitamin receive injection vitamin_b12 treatment alimta
d000.s016.t005,folic_acid,reduce side_effect patient take corticosteroid type vitamin receive injection vitamin_b12 treatment alimta
d000.s016.t006,type,reduce side_effect patient take corticosteroid folic_acid vitamin receive injection vitamin_b12 treatment alimta
d000.s016.t007,vitamin,reduce side_effect patient take corticosteroid folic_acid type receive injection vitamin_b12 treatment alimta
d000.s016.t008,injection,reduce side_effect patient take corticosteroid folic_acid type vitamin receive vitamin_b12 treatment alimta
d000.s016.t009,vitamin_b12,reduce side_effect patient take corticosteroid folic_acid type vitamin receive injection treatment alimta
d000.s016.t010,treatment,reduce side_effect patient take corticosteroid folic_acid type vitamin receive injection vitamin_b12 alimta
d000.s017.t000,give,alimta cisplatin anti-emetic medicine prevent vomit fluid prevent dehydration also give cisplatin dose
d000.s017.t001,medicine,alimta give cisplatin anti-emetic prevent vomit fluid prevent dehydration also give cisplatin dose
d000.s017.t002,prevent,alimta give cisplatin anti-emetic medicine vomit fluid prevent dehydration also give cisplatin dose
d000.s017.t003,vomit,alimta give cisplatin anti-emetic medicine prevent fluid prevent dehydration also give cisplatin dose
d000.s017.t004,fluid,alimta give cisplatin anti-emetic medicine prevent vomit prevent dehydration also give cisplatin dose
d000.s017.t005,prevent,alimta give cisplatin anti-emetic medicine vomit fluid prevent dehydration also give cisplatin dose
d000.s017.t006,dehydration,alimta give cisplatin anti-emetic medicine prevent vomit fluid prevent also give cisplatin dose
d000.s017.t007,also,alimta give cisplatin anti-emetic medicine prevent vomit fluid prevent dehydration give cisplatin dose
d000.s017.t008,give,alimta cisplatin anti-emetic medicine prevent vomit fluid prevent dehydration also give cisplatin dose
d000.s017.t009,before,alimta give cisplatin anti-emetic medicine prevent vomit fluid prevent dehydration also give cisplatin dose
d000.s017.t010,after,alimta give cisplatin anti-emetic medicine prevent vomit fluid prevent dehydration also give cisplatin dose
d000.s017.t011,dose,alimta give cisplatin anti-emetic medicine prevent vomit fluid prevent dehydration also give cisplatin
d000.s018.t000,treatment,delay discontinue dose reduce patient whose blood_count abnormal certain side_effect
d000.s018.t001,delay,treatment discontinue dose reduce patient whose blood_count abnormal certain side_effect
d000.s018.t002,discontinue,treatment delay dose reduce patient whose blood_count abnormal certain side_effect
d000.s018.t003,dose,treatment delay discontinue reduce patient whose blood_count abnormal certain side_effect
d000.s018.t004,reduce,treatment delay discontinue dose patient whose blood_count abnormal certain side_effect
d000.s018.t005,patient,treatment delay discontinue dose reduce whose blood_count abnormal certain side_effect
d000.s018.t006,blood_count,treatment delay discontinue dose reduce patient whose abnormal certain side_effect
d000.s018.t007,abnormal,treatment delay discontinue dose reduce patient whose blood_count certain side_effect
d000.s018.t008,have,treatment delay discontinue dose reduce patient whose blood_count abnormal certain side_effect
d000.s018.t009,certain,treatment delay discontinue dose reduce patient whose blood_count abnormal side_effect
d000.s018.t010,other,treatment delay discontinue dose reduce patient whose blood_count abnormal certain side_effect
d000.s018.t011,side_effect,treatment delay discontinue dose reduce patient whose blood_count abnormal certain
d000.s019.t000,not,alimta recommend use patient moderate severe kidney problem
d000.s019.t001,recommend,alimta use patient moderate severe kidney problem
d000.s019.t002,use,alimta recommend patient moderate severe kidney problem
d000.s019.t003,patient,alimta recommend use moderate severe kidney problem
d000.s019.t004,moderate,alimta recommend use patient severe kidney problem
d000.s019.t005,severe,alimta recommend use patient moderate kidney problem
d000.s019.t006,kidney,alimta recommend use patient moderate severe problem
d000.s019.t007,problem,alimta recommend use patient moderate severe kidney
d000.s020.t000,more,information see summary product characteristic also part epar
d000.s020.t001,information,see summary product characteristic also part epar
d000.s020.t002,see,information summary product characteristic also part epar
d000.s020.t003,summary,information see product characteristic also part epar
d000.s020.t004,product,information see summary characteristic also part epar
d000.s020.t005,also,information see summary product characteristic part epar
d000.s020.t006,part,information see summary product characteristic also epar
d000.s022.t000,active,substance alimta pemetrex cytotoxic medicine medicine kill cell divide cancer_cell belong_to group antimetabolite
d000.s022.t001,substance,active alimta pemetrex cytotoxic medicine medicine kill cell divide cancer_cell belong_to group antimetabolite
d000.s022.t002,cytotoxic,active substance alimta pemetrex medicine medicine kill cell divide cancer_cell belong_to group antimetabolite
d000.s022.t003,medicine,active substance alimta pemetrex cytotoxic medicine kill cell divide cancer_cell belong_to group antimetabolite
d000.s022.t004,medicine,active substance alimta pemetrex cytotoxic medicine kill cell divide cancer_cell belong_to group antimetabolite
d000.s022.t005,kill,active substance alimta pemetrex cytotoxic medicine medicine cell divide cancer_cell belong_to group antimetabolite
d000.s022.t006,cell,active substance alimta pemetrex cytotoxic medicine medicine kill divide cancer_cell belong_to group antimetabolite
d000.s022.t007,divide,active substance alimta pemetrex cytotoxic medicine medicine kill cell cancer_cell belong_to group antimetabolite
d000.s022.t008,cancer_cell,active substance alimta pemetrex cytotoxic medicine medicine kill cell divide belong_to group antimetabolite
d000.s022.t009,belong_to,active substance alimta pemetrex cytotoxic medicine medicine kill cell divide cancer_cell group antimetabolite
d000.s022.t010,group,active substance alimta pemetrex cytotoxic medicine medicine kill cell divide cancer_cell belong_to antimetabolite
d000.s022.t011,antimetabolite,active substance alimta pemetrex cytotoxic medicine medicine kill cell divide cancer_cell belong_to group
d000.s023.t000,body,pemetrex convert active form block activity enzyme involve produce nucleotide building_block dna rna genetic material cell
d000.s023.t001,convert,body pemetrex active form block activity enzyme involve produce nucleotide building_block dna rna genetic material cell
d000.s023.t002,active,body pemetrex convert form block activity enzyme involve produce nucleotide building_block dna rna genetic material cell
d000.s023.t003,form,body pemetrex convert active block activity enzyme involve produce nucleotide building_block dna rna genetic material cell
d000.s023.t004,block,body pemetrex convert active form activity enzyme involve produce nucleotide building_block dna rna genetic material cell
d000.s023.t005,activity,body pemetrex convert active form block enzyme involve produce nucleotide building_block dna rna genetic material cell
d000.s023.t006,enzyme,body pemetrex convert active form block activity involve produce nucleotide building_block dna rna genetic material cell
d000.s023.t007,involve,body pemetrex convert active form block activity enzyme produce nucleotide building_block dna rna genetic material cell
d000.s023.t008,produce,body pemetrex convert active form block activity enzyme involve nucleotide building_block dna rna genetic material cell
d000.s023.t009,nucleotide,body pemetrex convert active form block activity enzyme involve produce building_block dna rna genetic material cell
d000.s023.t010,building_block,body pemetrex convert active form block activity enzyme involve produce nucleotide dna rna genetic material cell
d000.s023.t011,dna,body pemetrex convert active form block activity enzyme involve produce nucleotide building_block rna genetic material cell
d000.s023.t012,rna,body pemetrex convert active form block activity enzyme involve produce nucleotide building_block dna genetic material cell
d000.s023.t013,genetic,body pemetrex convert active form block activity enzyme involve produce nucleotide building_block dna rna material cell
d000.s023.t014,material,body pemetrex convert active form block activity enzyme involve produce nucleotide building_block dna rna genetic cell
d000.s023.t015,cell,body pemetrex convert active form block activity enzyme involve produce nucleotide building_block dna rna genetic material
d000.s024.t000,study,alimta
d000.s025.t000,treatment,malignant pleural mesothelioma alimta study one main study patient receive chemotherapy disease
d000.s025.t001,malignant,treatment pleural mesothelioma alimta study one main study patient receive chemotherapy disease
d000.s025.t002,pleural,treatment malignant mesothelioma alimta study one main study patient receive chemotherapy disease
d000.s025.t003,mesothelioma,treatment malignant pleural alimta study one main study patient receive chemotherapy disease
d000.s025.t004,study,treatment malignant pleural mesothelioma alimta one main study patient receive chemotherapy disease
d000.s025.t005,main,treatment malignant pleural mesothelioma alimta study one study patient receive chemotherapy disease
d000.s025.t006,study,treatment malignant pleural mesothelioma alimta one main study patient receive chemotherapy disease
d000.s025.t007,patient,treatment malignant pleural mesothelioma alimta study one main study receive chemotherapy disease
d000.s025.t008,not,treatment malignant pleural mesothelioma alimta study one main study patient receive chemotherapy disease
d000.s025.t009,receive,treatment malignant pleural mesothelioma alimta study one main study patient chemotherapy disease
d000.s025.t010,chemotherapy,treatment malignant pleural mesothelioma alimta study one main study patient receive disease
d000.s025.t011,disease,treatment malignant pleural mesothelioma alimta study one main study patient receive chemotherapy
d000.s025.t012,before,treatment malignant pleural mesothelioma alimta study one main study patient receive chemotherapy disease
d000.s026.t000,effect,alimta combination cisplatin compare cisplatin alone
d000.s026.t001,combination,effect alimta cisplatin compare cisplatin alone
d000.s026.t002,compare,effect alimta combination cisplatin cisplatin alone
d000.s026.t003,alone,effect alimta combination cisplatin compare cisplatin
d000.s027.t000,treatment,non-small cell lung_cancer effect alimta compare docetaxel another anticancer medicine one study involve patient locally advanced metastatic disease receive chemotherapy past
d000.s027.t001,cell,treatment non-small lung_cancer effect alimta compare docetaxel another anticancer medicine one study involve patient locally advanced metastatic disease receive chemotherapy past
d000.s027.t002,lung_cancer,treatment non-small cell effect alimta compare docetaxel another anticancer medicine one study involve patient locally advanced metastatic disease receive chemotherapy past
d000.s027.t003,effect,treatment non-small cell lung_cancer alimta compare docetaxel another anticancer medicine one study involve patient locally advanced metastatic disease receive chemotherapy past
d000.s027.t004,compare,treatment non-small cell lung_cancer effect alimta docetaxel another anticancer medicine one study involve patient locally advanced metastatic disease receive chemotherapy past
d000.s027.t005,anticancer,treatment non-small cell lung_cancer effect alimta compare docetaxel another medicine one study involve patient locally advanced metastatic disease receive chemotherapy past
d000.s027.t006,medicine,treatment non-small cell lung_cancer effect alimta compare docetaxel another anticancer one study involve patient locally advanced metastatic disease receive chemotherapy past
d000.s027.t007,study,treatment non-small cell lung_cancer effect alimta compare docetaxel another anticancer medicine one involve patient locally advanced metastatic disease receive chemotherapy past
d000.s027.t008,involve,treatment non-small cell lung_cancer effect alimta compare docetaxel another anticancer medicine one study patient locally advanced metastatic disease receive chemotherapy past
d000.s027.t009,patient,treatment non-small cell lung_cancer effect alimta compare docetaxel another anticancer medicine one study involve locally advanced metastatic disease receive chemotherapy past
d000.s027.t010,locally,treatment non-small cell lung_cancer effect alimta compare docetaxel another anticancer medicine one study involve patient advanced metastatic disease receive chemotherapy past
d000.s027.t011,advanced,treatment non-small cell lung_cancer effect alimta compare docetaxel another anticancer medicine one study involve patient locally metastatic disease receive chemotherapy past
d000.s027.t012,metastatic,treatment non-small cell lung_cancer effect alimta compare docetaxel another anticancer medicine one study involve patient locally advanced disease receive chemotherapy past
d000.s027.t013,disease,treatment non-small cell lung_cancer effect alimta compare docetaxel another anticancer medicine one study involve patient locally advanced metastatic receive chemotherapy past
d000.s027.t014,receive,treatment non-small cell lung_cancer effect alimta compare docetaxel another anticancer medicine one study involve patient locally advanced metastatic disease chemotherapy past
d000.s027.t015,chemotherapy,treatment non-small cell lung_cancer effect alimta compare docetaxel another anticancer medicine one study involve patient locally advanced metastatic disease receive past
d000.s027.t016,past,treatment non-small cell lung_cancer effect alimta compare docetaxel another anticancer medicine one study involve patient locally advanced metastatic disease receive chemotherapy
d000.s028.t000,also,"alimta compare gemcitabine another anticancer medicine combination cisplatin study involve 1,725 patient receive chemotherapy lung_cancer past"
d000.s028.t001,compare,"alimta also gemcitabine another anticancer medicine combination cisplatin study involve 1,725 patient receive chemotherapy lung_cancer past"
d000.s028.t002,anticancer,"alimta also compare gemcitabine another medicine combination cisplatin study involve 1,725 patient receive chemotherapy lung_cancer past"
d000.s028.t003,medicine,"alimta also compare gemcitabine another anticancer combination cisplatin study involve 1,725 patient receive chemotherapy lung_cancer past"
d000.s028.t004,combination,"alimta also compare gemcitabine another anticancer medicine cisplatin study involve 1,725 patient receive chemotherapy lung_cancer past"
d000.s028.t005,study,"alimta also compare gemcitabine another anticancer medicine combination cisplatin involve 1,725 patient receive chemotherapy lung_cancer past"
d000.s028.t006,involve,"alimta also compare gemcitabine another anticancer medicine combination cisplatin study 1,725 patient receive chemotherapy lung_cancer past"
d000.s028.t007,patient,"alimta also compare gemcitabine another anticancer medicine combination cisplatin study involve 1,725 receive chemotherapy lung_cancer past"
d000.s028.t008,not,"alimta also compare gemcitabine another anticancer medicine combination cisplatin study involve 1,725 patient receive chemotherapy lung_cancer past"
d000.s028.t009,receive,"alimta also compare gemcitabine another anticancer medicine combination cisplatin study involve 1,725 patient chemotherapy lung_cancer past"
d000.s028.t010,chemotherapy,"alimta also compare gemcitabine another anticancer medicine combination cisplatin study involve 1,725 patient receive lung_cancer past"
d000.s028.t011,lung_cancer,"alimta also compare gemcitabine another anticancer medicine combination cisplatin study involve 1,725 patient receive chemotherapy past"
d000.s028.t012,past,"alimta also compare gemcitabine another anticancer medicine combination cisplatin study involve 1,725 patient receive chemotherapy lung_cancer"
d000.s029.t000,study,three main measure effectiveness long patient survive
d000.s029.t001,main,three study measure effectiveness long patient survive
d000.s029.t002,measure,three study main effectiveness long patient survive
d000.s029.t003,effectiveness,three study main measure long patient survive
d000.s029.t004,long,three study main measure effectiveness patient survive
d000.s029.t005,patient,three study main measure effectiveness long survive
d000.s029.t006,survive,three study main measure effectiveness long patient
d000.s030.t000,benefit,alimta show study
d000.s030.t001,show,benefit alimta study
d000.s030.t002,study,benefit alimta show
d000.s031.t000,increase,alimta survival time patient malignant pleural mesothelioma
d000.s031.t001,survival,alimta increase time patient malignant pleural mesothelioma
d000.s031.t002,time,alimta increase survival patient malignant pleural mesothelioma
d000.s031.t003,patient,alimta increase survival time malignant pleural mesothelioma
d000.s031.t004,malignant,alimta increase survival time patient pleural mesothelioma
d000.s031.t005,pleural,alimta increase survival time patient malignant mesothelioma
d000.s031.t006,mesothelioma,alimta increase survival time patient malignant pleural
d000.s032.t000,patient,receive alimta cisplatin survive average 12.1 month compare 9.3 month receive cisplatin alone
d000.s032.t001,receive,patient alimta cisplatin survive average 12.1 month compare 9.3 month receive cisplatin alone
d000.s032.t002,survive,patient receive alimta cisplatin average 12.1 month compare 9.3 month receive cisplatin alone
d000.s032.t003,average,patient receive alimta cisplatin survive 12.1 month compare 9.3 month receive cisplatin alone
d000.s032.t004,month,patient receive alimta cisplatin survive average 12.1 compare 9.3 month receive cisplatin alone
d000.s032.t005,compare,patient receive alimta cisplatin survive average 12.1 month 9.3 month receive cisplatin alone
d000.s032.t006,month,patient receive alimta cisplatin survive average 12.1 compare 9.3 month receive cisplatin alone
d000.s032.t007,alone,patient receive alimta cisplatin survive average 12.1 month compare 9.3 month receive cisplatin
d000.s033.t000,treatment,patient non-small cell lung_cancer alimta effective comparator
d000.s033.t001,patient,treatment non-small cell lung_cancer alimta effective comparator
d000.s033.t002,cell,treatment patient non-small lung_cancer alimta effective comparator
d000.s033.t003,lung_cancer,treatment patient non-small cell alimta effective comparator
d000.s033.t004,as,treatment patient non-small cell lung_cancer alimta effective comparator
d000.s033.t005,effective,treatment patient non-small cell lung_cancer alimta comparator
d000.s033.t006,as,treatment patient non-small cell lung_cancer alimta effective comparator
d000.s034.t000,patient,receive chemotherapy past average survival time 8.3 month alimta compare 7.9 month docetaxel
d000.s034.t001,receive,patient chemotherapy past average survival time 8.3 month alimta compare 7.9 month docetaxel
d000.s034.t002,chemotherapy,patient receive past average survival time 8.3 month alimta compare 7.9 month docetaxel
d000.s034.t003,past,patient receive chemotherapy average survival time 8.3 month alimta compare 7.9 month docetaxel
d000.s034.t004,average,patient receive chemotherapy past survival time 8.3 month alimta compare 7.9 month docetaxel
d000.s034.t005,survival,patient receive chemotherapy past average time 8.3 month alimta compare 7.9 month docetaxel
d000.s034.t006,time,patient receive chemotherapy past average survival 8.3 month alimta compare 7.9 month docetaxel
d000.s034.t007,month,patient receive chemotherapy past average survival time 8.3 alimta compare 7.9 month docetaxel
d000.s034.t008,compare,patient receive chemotherapy past average survival time 8.3 month alimta 7.9 month docetaxel
d000.s034.t009,month,patient receive chemotherapy past average survival time 8.3 alimta compare 7.9 month docetaxel
d000.s035.t000,patient,receive chemotherapy past average survival time 10.3 month group
d000.s035.t001,not,patient receive chemotherapy past average survival time 10.3 month group
d000.s035.t002,receive,patient chemotherapy past average survival time 10.3 month group
d000.s035.t003,chemotherapy,patient receive past average survival time 10.3 month group
d000.s035.t004,past,patient receive chemotherapy average survival time 10.3 month group
d000.s035.t005,average,patient receive chemotherapy past survival time 10.3 month group
d000.s035.t006,survival,patient receive chemotherapy past average time 10.3 month group
d000.s035.t007,time,patient receive chemotherapy past average survival 10.3 month group
d000.s035.t008,month,patient receive chemotherapy past average survival time 10.3 group
d000.s035.t009,group,patient receive chemotherapy past average survival time 10.3 month
d000.s036.t000,however,study patient whose cancer affect squamous_cell long survival time receive alimta receive comparator
d000.s036.t001,study,however patient whose cancer affect squamous_cell long survival time receive alimta receive comparator
d000.s036.t002,patient,however study whose cancer affect squamous_cell long survival time receive alimta receive comparator
d000.s036.t003,cancer,however study patient whose affect squamous_cell long survival time receive alimta receive comparator
d000.s036.t004,not,however study patient whose cancer affect squamous_cell long survival time receive alimta receive comparator
d000.s036.t005,affect,however study patient whose cancer squamous_cell long survival time receive alimta receive comparator
d000.s036.t006,squamous_cell,however study patient whose cancer affect long survival time receive alimta receive comparator
d000.s036.t007,have,however study patient whose cancer affect squamous_cell long survival time receive alimta receive comparator
d000.s036.t008,long,however study patient whose cancer affect squamous_cell survival time receive alimta receive comparator
d000.s036.t009,survival,however study patient whose cancer affect squamous_cell long time receive alimta receive comparator
d000.s036.t010,time,however study patient whose cancer affect squamous_cell long survival receive alimta receive comparator
d000.s037.t000,contrast,patient whose cancer affect squamous_cell short survival time receive alimta
d000.s037.t001,patient,contrast whose cancer affect squamous_cell short survival time receive alimta
d000.s037.t002,cancer,contrast patient whose affect squamous_cell short survival time receive alimta
d000.s037.t003,affect,contrast patient whose cancer squamous_cell short survival time receive alimta
d000.s037.t004,squamous_cell,contrast patient whose cancer affect short survival time receive alimta
d000.s037.t005,have,contrast patient whose cancer affect squamous_cell short survival time receive alimta
d000.s037.t006,short,contrast patient whose cancer affect squamous_cell survival time receive alimta
d000.s037.t007,survival,contrast patient whose cancer affect squamous_cell short time receive alimta
d000.s037.t008,time,contrast patient whose cancer affect squamous_cell short survival receive alimta
d001.s000.t000,mathematical,kalgebra calculator base content markup mathml language
d001.s000.t001,base,kalgebra mathematical calculator content markup mathml language
d001.s000.t002,markup,kalgebra mathematical calculator base content mathml language
d001.s001.t000,nowadays,capable make simple mathml operation arithmetic logical representate 2d 3d graph
d001.s001.t001,capable,nowadays make simple mathml operation arithmetic logical representate 2d 3d graph
d001.s001.t002,make,nowadays capable simple mathml operation arithmetic logical representate 2d 3d graph
d001.s001.t003,simple,nowadays capable make mathml operation arithmetic logical representate 2d 3d graph
d001.s001.t004,operation,nowadays capable make simple mathml arithmetic logical representate 2d 3d graph
d001.s001.t005,arithmetic,nowadays capable make simple mathml operation logical representate 2d 3d graph
d001.s001.t006,3d,nowadays capable make simple mathml operation arithmetic logical representate 2d graph
d001.s001.t007,graph,nowadays capable make simple mathml operation arithmetic logical representate 2d 3d
d001.s002.t000,actually,necessary know mathml use kalgebra
d001.s002.t001,not,actually necessary know mathml use kalgebra
d001.s002.t002,necessary,actually know mathml use kalgebra
d001.s002.t003,know,actually necessary mathml use kalgebra
d001.s002.t004,use,actually necessary know mathml kalgebra
d001.s003.t000,base,kalgebra mathml graph calculator
d001.s003.t001,graph,kalgebra mathml base calculator
d001.s004.t000,initially,although mathml orient use everyone little mathematical knowledge
d001.s004.t001,orient,although initially mathml use everyone little mathematical knowledge
d001.s004.t002,now,although initially mathml orient use everyone little mathematical knowledge
d001.s004.t003,use,although initially mathml orient everyone little mathematical knowledge
d001.s004.t004,little,although initially mathml orient use everyone mathematical knowledge
d001.s004.t005,mathematical,although initially mathml orient use everyone little knowledge
d001.s004.t006,knowledge,although initially mathml orient use everyone little mathematical
d001.s005.t000,here,screenshot kalgebra main window
d001.s005.t001,main,screenshot kalgebra window
d001.s005.t002,window,screenshot kalgebra main
d001.s006.t000,main,kalgebra window
d001.s006.t001,window,kalgebra main
d001.s007.t000,main,kalgebra window consist console tab 2d graph tab 3d graph tab dictionary tab
d001.s007.t001,window,kalgebra main consist console tab 2d graph tab 3d graph tab dictionary tab
d001.s007.t002,consist,kalgebra main window console tab 2d graph tab 3d graph tab dictionary tab
d001.s007.t003,console,kalgebra main window consist tab 2d graph tab 3d graph tab dictionary tab
d001.s007.t004,graph,kalgebra main window consist console tab 2d tab 3d graph tab dictionary tab
d001.s007.t005,3d,kalgebra main window consist console tab 2d graph tab graph tab dictionary tab
d001.s007.t006,graph,kalgebra main window consist console tab 2d tab 3d graph tab dictionary tab
d001.s007.t007,dictionary,kalgebra main window consist console tab 2d graph tab 3d graph tab tab
d001.s008.t000,below,tab find input field type function calculation
d001.s008.t001,find,tab input field type function calculation
d001.s008.t002,input,tab find field type function calculation
d001.s008.t003,field,tab find input type function calculation
d001.s008.t004,type,tab find input field function calculation
d001.s008.t005,function,tab find input field type calculation
d001.s008.t006,do,tab find input field type function calculation
d001.s008.t007,calculation,tab find input field type function
d001.s009.t000,want,understand work best thing realize input convert mathml although necessary know mathml
d001.s009.t001,understand,want work best thing realize input convert mathml although necessary know mathml
d001.s009.t002,work,want understand best thing realize input convert mathml although necessary know mathml
d001.s009.t003,best,want understand work thing realize input convert mathml although necessary know mathml
d001.s009.t004,thing,want understand work best realize input convert mathml although necessary know mathml
d001.s009.t005,do,want understand work best thing realize input convert mathml although necessary know mathml
d001.s009.t006,realize,want understand work best thing input convert mathml although necessary know mathml
d001.s009.t007,input,want understand work best thing realize convert mathml although necessary know mathml
d001.s009.t008,convert,want understand work best thing realize input mathml although necessary know mathml
d001.s009.t009,not,want understand work best thing realize input convert mathml although necessary know mathml
d001.s009.t010,necessary,want understand work best thing realize input convert mathml although know mathml
d001.s009.t011,know,want understand work best thing realize input convert mathml although necessary mathml
d001.s010.t000,base,i syntax basically common_sense hard anyone
d001.s010.t001,basically,i base syntax common_sense hard anyone
d001.s010.t002,common_sense,i base syntax basically hard anyone
d001.s010.t003,not,i base syntax basically common_sense hard anyone
d001.s010.t004,hard,i base syntax basically common_sense anyone
d001.s011.t000,look,i closely maximum maple syntax look similar
d001.s011.t001,closely,i look maximum maple syntax look similar
d001.s011.t002,look,i closely maximum maple syntax look similar
d001.s011.t003,very,i look closely maximum maple syntax look similar
d001.s011.t004,similar,i look closely maximum maple syntax look
d001.s012.t000,addition,subtraction multiplication division
d001.s012.t001,subtraction,addition multiplication division
d001.s012.t002,multiplication,addition subtraction division
d001.s012.t003,division,addition subtraction multiplication
d001.s013.t000,power,** use
d001.s013.t001,use,** power
d001.s014.t000,also,possible use unicode character
d001.s014.t001,possible,also use unicode character
d001.s014.t002,use,also possible unicode character
d001.s015.t000,power,one way make root
d001.s015.t001,way,power one make root
d001.s015.t002,make,power one way root
d001.s015.t003,root,power one way make
d001.s015.t004,too,power one way make root
d001.s016.t000,way,-gt specify bounded variable function
d001.s016.t001,specify,-gt way bounded variable function
d001.s016.t002,bounded,-gt way specify variable function
d001.s016.t003,variable,-gt way specify bounded function
d001.s016.t004,function,-gt way specify bounded variable
d001.s017.t000,use,specify high priority
d001.s017.t001,specify,use high priority
d001.s017.t002,high,use specify priority
d001.s017.t003,priority,use specify high
d001.s018.t000,parser,abc(params) find function check abc operator
d001.s018.t001,find,abc(params) parser function check abc operator
d001.s018.t002,function,abc(params) parser find check abc operator
d001.s018.t003,check,abc(params) parser find function abc operator
d001.s018.t004,operator,abc(params) parser find function check abc
d001.s019.t000,treat,operator treat user function
d001.s019.t001,operator,treat treat user function
d001.s019.t002,not,treat operator treat user function
d001.s019.t003,treat,operator treat user function
d001.s019.t004,user,treat operator treat function
d001.s019.t005,function,treat operator treat user
d001.s020.t000,use,define variable value
d001.s020.t001,define,use variable value
d001.s020.t002,value,use define variable
d001.s021.t000,condition,piecewise definition
d001.s021.t001,definition,piecewise condition
d001.s022.t000,way,piecewise define conditional operation kalgebra
d001.s022.t001,define,piecewise way conditional operation kalgebra
d001.s022.t002,conditional,piecewise way define operation kalgebra
d001.s022.t003,operation,piecewise way define conditional kalgebra
d001.s023.t000,introduce,condition use condition only_if true find without condition enter last instance
d001.s023.t001,condition,introduce use condition only_if true find without condition enter last instance
d001.s023.t002,use,introduce condition condition only_if true find without condition enter last instance
d001.s023.t003,condition,introduce use condition only_if true find without condition enter last instance
d001.s023.t004,only_if,introduce condition use condition true find without condition enter last instance
d001.s023.t005,true,introduce condition use condition only_if find without condition enter last instance
d001.s023.t006,find,introduce condition use condition only_if true without condition enter last instance
d001.s023.t007,condition,introduce use condition only_if true find without condition enter last instance
d001.s023.t008,enter,introduce condition use condition only_if true find without condition last instance
d001.s023.t009,last,introduce condition use condition only_if true find without condition enter instance
d001.s023.t010,instance,introduce condition use condition only_if true find without condition enter last
d001.s025.t000,use,define container
d001.s025.t001,define,use container
d001.s026.t000,mainly,useful work piecewise
d001.s026.t001,useful,mainly work piecewise
d001.s026.t002,work,mainly useful piecewise
d001.s027.t000,now,could ask i user mind mathml
d001.s027.t001,ask,could i user mind mathml
d001.s027.t002,user,could ask i mind mathml
d001.s028.t000,easy,operate function like cos sin trigonometric function sum product
d001.s028.t001,operate,easy function like cos sin trigonometric function sum product
d001.s028.t002,function,easy operate like cos sin trigonometric function sum product
d001.s028.t003,cos,easy operate function like sin trigonometric function sum product
d001.s028.t004,sin,easy operate function like cos trigonometric function sum product
d001.s028.t005,other,easy operate function like cos sin trigonometric function sum product
d001.s028.t006,trigonometric,easy operate function like cos sin function sum product
d001.s028.t007,function,easy operate like cos sin trigonometric function sum product
d001.s028.t008,sum,easy operate function like cos sin trigonometric function product
d001.s028.t009,product,easy operate function like cos sin trigonometric function sum
d001.s029.t000,not,matter kind
d001.s029.t001,matter,kind
d001.s029.t002,kind,matter
d001.s030.t000,use,plus times everything operator
d001.s030.t001,plus,use times everything operator
d001.s030.t002,times,use plus everything operator
d001.s030.t003,have,use plus times everything operator
d001.s030.t004,operator,use plus times everything
d001.s031.t000,useful,kalgebra console calculator
d001.s032.t000,there,list declare variable
d001.s032.t001,have,list declare variable
d001.s032.t002,list,declare variable
d001.s032.t003,variable,list declare
d001.s033.t000,see,double click dialog let change value way trick log
d001.s033.t001,let,double click see dialog change value way trick log
d001.s033.t002,change,double click see dialog let value way trick log
d001.s033.t003,value,double click see dialog let change way trick log
d001.s033.t004,just,double click see dialog let change value way trick log
d001.s033.t005,way,double click see dialog let change value trick log
d001.s033.t006,trick,double click see dialog let change value way log
d001.s033.t007,log,double click see dialog let change value way trick
d001.s034.t000,time,every enter expression variable value change last result
d001.s034.t001,enter,every time expression variable value change last result
d001.s034.t002,expression,every time enter variable value change last result
d001.s034.t003,variable,every time enter expression value change last result
d001.s034.t004,value,every time enter expression variable change last result
d001.s034.t005,change,every time enter expression variable value last result
d001.s034.t006,last,every time enter expression variable value change result
d001.s034.t007,result,every time enter expression variable value change last
d001.s035.t000,new,ctrl n window
d001.s035.t001,window,ctrl n new
d001.s036.t000,log,flush
d001.s037.t000,load,ctrl l script
d001.s038.t000,execute,instruction file sequentially
d001.s038.t001,instruction,execute file sequentially
d001.s038.t002,file,execute instruction sequentially
d001.s038.t003,sequentially,execute instruction file
d001.s039.t000,nice,want define library resume previous work
d001.s039.t001,want,nice define library resume previous work
d001.s039.t002,define,nice want library resume previous work
d001.s039.t003,library,nice want define resume previous work
d001.s039.t004,resume,nice want define library previous work
d001.s039.t005,previous,nice want define library resume work
d001.s039.t006,work,nice want define library resume previous
d001.s040.t000,save,ctrl g script
d001.s041.t000,save,instruction type since session begin able reuse
d001.s041.t001,instruction,save type since session begin able reuse
d001.s041.t002,type,save instruction since session begin able reuse
d001.s041.t003,begin,save instruction type since session able reuse
d001.s041.t004,able,save instruction type since session begin reuse
d001.s041.t005,reuse,save instruction type since session begin able
d001.s042.t000,generate,text_file easy fix use text_editor like kate
d001.s042.t001,text_file,generate easy fix use text_editor like kate
d001.s042.t002,easy,generate text_file fix use text_editor like kate
d001.s042.t003,fix,generate text_file easy use text_editor like kate
d001.s042.t004,use,generate text_file easy fix text_editor like kate
d001.s042.t005,text_editor,generate text_file easy fix use like kate
d001.s043.t000,save,ctrl log
d001.s043.t001,log,ctrl save
d001.s044.t000,save,log result html file able print publish
d001.s044.t001,log,save result html file able print publish
d001.s044.t002,result,save log html file able print publish
d001.s044.t003,html,save log result file able print publish
d001.s044.t004,able,save log result html file print publish
d001.s044.t005,print,save log result html file able publish
d001.s044.t006,publish,save log result html file able print
d001.s045.t000,quit,ctrl q
d001.s046.t000,program,shut
d001.s046.t001,down,shut program
d001.s047.t000,add,new 2d graph kalgebra go 2d graph tab click add tab add new function
d001.s047.t001,new,add 2d graph kalgebra go 2d graph tab click add tab add new function
d001.s047.t002,graph,add new 2d kalgebra go 2d graph tab click add tab add new function
d001.s047.t003,do,add new 2d graph kalgebra go 2d graph tab click add tab add new function
d001.s047.t004,go,add new 2d graph kalgebra 2d graph tab click add tab add new function
d001.s047.t005,graph,add new 2d kalgebra go 2d graph tab click add tab add new function
d001.s047.t006,add,new 2d graph kalgebra go 2d graph tab click add tab add new function
d001.s047.t007,add,new 2d graph kalgebra go 2d graph tab click add tab add new function
d001.s047.t008,new,add 2d graph kalgebra go 2d graph tab click add tab add new function
d001.s047.t009,function,add new 2d graph kalgebra go 2d graph tab click add tab add new
d001.s048.t000,then,focus go input text box type function
d001.s048.t001,focus,go input text box type function
d001.s048.t002,input,focus go text box type function
d001.s048.t003,text,focus go input box type function
d001.s048.t004,box,focus go input text type function
d001.s048.t005,type,focus go input text box function
d001.s048.t006,function,focus go input text box type
d001.s049.t000,want,use typical f(x) function necessary specify
d001.s049.t001,use,want typical f(x) function necessary specify
d001.s049.t002,typical,want use f(x) function necessary specify
d001.s049.t003,not,want use typical f(x) function necessary specify
d001.s049.t004,necessary,want use typical f(x) function specify
d001.s049.t005,specify,want use typical f(x) function necessary
d001.s050.t000,enter,function click ok button display graph main window
d001.s050.t001,function,enter click ok button display graph main window
d001.s050.t002,ok,enter function click button display graph main window
d001.s050.t003,display,enter function click ok button graph main window
d001.s050.t004,graph,enter function click ok button display main window
d001.s050.t005,main,enter function click ok button display graph window
d001.s050.t006,window,enter function click ok button display graph main
d001.s051.t000,set,several graph view
d001.s051.t001,several,set graph view
d001.s051.t002,graph,set several view
d001.s051.t003,same,set several graph view
d001.s051.t004,view,set several graph
d001.s052.t000,just,use add button list mode
d001.s052.t001,use,add button list mode
d001.s052.t002,add,use button list mode
d001.s052.t003,list,use add button mode
d001.s052.t004,mode,use add button list
d001.s053.t000,set,graph color
d001.s053.t001,graph,set color
d001.s053.t002,color,set graph
d002.s000.t000,foundation,recently involve organise conference deal critical challenge
d002.s000.t001,recently,foundation involve organise conference deal critical challenge
d002.s000.t002,involve,foundation recently organise conference deal critical challenge
d002.s000.t003,organise,foundation recently involve conference deal critical challenge
d002.s000.t004,conference,foundation recently involve organise deal critical challenge
d002.s000.t005,deal,foundation recently involve organise conference critical challenge
d002.s000.t006,critical,foundation recently involve organise conference deal challenge
d002.s000.t007,challenge,foundation recently involve organise conference deal critical
d002.s001.t000,participant,main interest_group attend debate issue role key actor include public authority social partner voluntary community organisation as_well service user
d002.s001.t001,main,participant interest_group attend debate issue role key actor include public authority social partner voluntary community organisation as_well service user
d002.s001.t002,interest_group,participant main attend debate issue role key actor include public authority social partner voluntary community organisation as_well service user
d002.s001.t003,attend,participant main interest_group debate issue role key actor include public authority social partner voluntary community organisation as_well service user
d002.s001.t004,debate,participant main interest_group attend issue role key actor include public authority social partner voluntary community organisation as_well service user
d002.s001.t005,issue,participant main interest_group attend debate role key actor include public authority social partner voluntary community organisation as_well service user
d002.s001.t006,role,participant main interest_group attend debate issue key actor include public authority social partner voluntary community organisation as_well service user
d002.s001.t007,key,participant main interest_group attend debate issue role actor include public authority social partner voluntary community organisation as_well service user
d002.s001.t008,actor,participant main interest_group attend debate issue role key include public authority social partner voluntary community organisation as_well service user
d002.s001.t009,include,participant main interest_group attend debate issue role key actor public authority social partner voluntary community organisation as_well service user
d002.s001.t010,public,participant main interest_group attend debate issue role key actor include authority social partner voluntary community organisation as_well service user
d002.s001.t011,authority,participant main interest_group attend debate issue role key actor include public social partner voluntary community organisation as_well service user
d002.s001.t012,social,participant main interest_group attend debate issue role key actor include public authority partner voluntary community organisation as_well service user
d002.s001.t013,voluntary,participant main interest_group attend debate issue role key actor include public authority social partner community organisation as_well service user
d002.s001.t014,community,participant main interest_group attend debate issue role key actor include public authority social partner voluntary organisation as_well service user
d002.s001.t015,organisation,participant main interest_group attend debate issue role key actor include public authority social partner voluntary community as_well service user
d002.s001.t016,as_well,participant main interest_group attend debate issue role key actor include public authority social partner voluntary community organisation service user
d002.s001.t017,service,participant main interest_group attend debate issue role key actor include public authority social partner voluntary community organisation as_well user
d002.s001.t018,user,participant main interest_group attend debate issue role key actor include public authority social partner voluntary community organisation as_well service
d002.s002.t000,relatively,case report attempt involve user service planning involvement service provision find common
d002.s002.t001,few,relatively case report attempt involve user service planning involvement service provision find common
d002.s002.t002,case,relatively report attempt involve user service planning involvement service provision find common
d002.s002.t003,report,relatively case attempt involve user service planning involvement service provision find common
d002.s002.t004,attempt,relatively case report involve user service planning involvement service provision find common
d002.s002.t005,involve,relatively case report attempt user service planning involvement service provision find common
d002.s002.t006,user,relatively case report attempt involve service planning involvement service provision find common
d002.s002.t007,service,relatively case report attempt involve user planning involvement service provision find common
d002.s002.t008,planning,relatively case report attempt involve user service involvement service provision find common
d002.s002.t009,involvement,relatively case report attempt involve user service planning service provision find common
d002.s002.t010,service,relatively case report attempt involve user planning involvement service provision find common
d002.s002.t011,provision,relatively case report attempt involve user service planning involvement service find common
d002.s002.t012,find,relatively case report attempt involve user service planning involvement service provision common
d002.s002.t013,more,relatively case report attempt involve user service planning involvement service provision find common
d002.s002.t014,common,relatively case report attempt involve user service planning involvement service provision find
d002.s003.t000,note,also take variety different role play public welfare
d002.s003.t001,also,note take variety different role play public welfare
d002.s003.t002,variety,note also take different role play public welfare
d002.s003.t003,different,note also take variety role play public welfare
d002.s003.t004,role,note also take variety different play public welfare
d002.s003.t005,play,note also take variety different role public welfare
d002.s003.t006,public,note also take variety different role play welfare
d002.s003.t007,welfare,note also take variety different role play public
d002.s004.t000,foundation,organise together european commission spanish ministry social affairs galician regional government european conference social exclusion major challenge public welfare service
d002.s004.t001,european,foundation organise together commission spanish ministry social affairs galician regional government european conference social exclusion major challenge public welfare service
d002.s004.t002,commission,foundation organise together european spanish ministry social affairs galician regional government european conference social exclusion major challenge public welfare service
d002.s004.t003,spanish,foundation organise together european commission ministry social affairs galician regional government european conference social exclusion major challenge public welfare service
d002.s004.t004,ministry,foundation organise together european commission spanish social affairs galician regional government european conference social exclusion major challenge public welfare service
d002.s004.t005,social,foundation organise together european commission spanish ministry affairs galician regional government european conference social exclusion major challenge public welfare service
d002.s004.t006,affairs,foundation organise together european commission spanish ministry social galician regional government european conference social exclusion major challenge public welfare service
d002.s004.t007,regional,foundation organise together european commission spanish ministry social affairs galician government european conference social exclusion major challenge public welfare service
d002.s004.t008,government,foundation organise together european commission spanish ministry social affairs galician regional european conference social exclusion major challenge public welfare service
d002.s004.t009,european,foundation organise together commission spanish ministry social affairs galician regional government european conference social exclusion major challenge public welfare service
d002.s004.t010,conference,foundation organise together european commission spanish ministry social affairs galician regional government european social exclusion major challenge public welfare service
d002.s004.t011,social,foundation organise together european commission spanish ministry affairs galician regional government european conference social exclusion major challenge public welfare service
d002.s004.t012,exclusion,foundation organise together european commission spanish ministry social affairs galician regional government european conference social major challenge public welfare service
d002.s004.t013,major,foundation organise together european commission spanish ministry social affairs galician regional government european conference social exclusion challenge public welfare service
d002.s004.t014,challenge,foundation organise together european commission spanish ministry social affairs galician regional government european conference social exclusion major public welfare service
d002.s004.t015,public,foundation organise together european commission spanish ministry social affairs galician regional government european conference social exclusion major challenge welfare service
d002.s004.t016,welfare,foundation organise together european commission spanish ministry social affairs galician regional government european conference social exclusion major challenge public service
d002.s004.t017,service,foundation organise together european commission spanish ministry social affairs galician regional government european conference social exclusion major challenge public welfare
d002.s005.t000,foundation,recently publish comparative study part epoc project assess extent direct participation humanise work increase profitability
d002.s005.t001,recently,foundation publish comparative study part epoc project assess extent direct participation humanise work increase profitability
d002.s005.t002,publish,foundation recently comparative study part epoc project assess extent direct participation humanise work increase profitability
d002.s005.t003,comparative,foundation recently publish study part epoc project assess extent direct participation humanise work increase profitability
d002.s005.t004,study,foundation recently publish comparative part epoc project assess extent direct participation humanise work increase profitability
d002.s005.t005,part,foundation recently publish comparative study epoc project assess extent direct participation humanise work increase profitability
d002.s005.t006,project,foundation recently publish comparative study part epoc assess extent direct participation humanise work increase profitability
d002.s005.t007,assess,foundation recently publish comparative study part epoc project extent direct participation humanise work increase profitability
d002.s005.t008,extent,foundation recently publish comparative study part epoc project assess direct participation humanise work increase profitability
d002.s005.t009,direct,foundation recently publish comparative study part epoc project assess extent participation humanise work increase profitability
d002.s005.t010,participation,foundation recently publish comparative study part epoc project assess extent direct humanise work increase profitability
d002.s005.t011,humanise,foundation recently publish comparative study part epoc project assess extent direct participation work increase profitability
d002.s005.t012,work,foundation recently publish comparative study part epoc project assess extent direct participation humanise increase profitability
d002.s005.t013,increase,foundation recently publish comparative study part epoc project assess extent direct participation humanise work profitability
d002.s005.t014,profitability,foundation recently publish comparative study part epoc project assess extent direct participation humanise work increase
d002.s006.t000,study,base personal interview senior official social partner representative national level peak organisation fifteen european country
d002.s006.t001,base,study personal interview senior official social partner representative national level peak organisation fifteen european country
d002.s006.t002,personal,study base interview senior official social partner representative national level peak organisation fifteen european country
d002.s006.t003,interview,study base personal senior official social partner representative national level peak organisation fifteen european country
d002.s006.t004,senior,study base personal interview official social partner representative national level peak organisation fifteen european country
d002.s006.t005,official,study base personal interview senior social partner representative national level peak organisation fifteen european country
d002.s006.t006,social,study base personal interview senior official partner representative national level peak organisation fifteen european country
d002.s006.t007,representative,study base personal interview senior official social partner national level peak organisation fifteen european country
d002.s006.t008,national,study base personal interview senior official social partner representative level peak organisation fifteen european country
d002.s006.t009,level,study base personal interview senior official social partner representative national peak organisation fifteen european country
d002.s006.t010,organisation,study base personal interview senior official social partner representative national level peak fifteen european country
d002.s006.t011,fifteen,study base personal interview senior official social partner representative national level peak organisation european country
d002.s006.t012,european,study base personal interview senior official social partner representative national level peak organisation fifteen country
d002.s006.t013,country,study base personal interview senior official social partner representative national level peak organisation fifteen european
d002.s007.t000,important,industrial sector metal industry banking sector also include
d002.s007.t001,industrial,important sector metal industry banking sector also include
d002.s007.t002,sector,important industrial metal industry banking sector also include
d002.s007.t003,metal,important industrial sector industry banking sector also include
d002.s007.t004,industry,important industrial sector metal banking sector also include
d002.s007.t005,banking,important industrial sector metal industry sector also include
d002.s007.t006,sector,important industrial metal industry banking sector also include
d002.s007.t007,also,important industrial sector metal industry banking sector include
d002.s007.t008,include,important industrial sector metal industry banking sector also
d002.s008.t000,speaker,key social exclusion conference left right cristina louro employment industrial relations social_affair directorate european commission fernando gome high degree committee region barbara weiler member european parliament josé marium gil-roble vice_president european parliament john carroll economic social committee
d002.s008.t001,social,key speaker exclusion conference left right cristina louro employment industrial relations social_affair directorate european commission fernando gome high degree committee region barbara weiler member european parliament josé marium gil-roble vice_president european parliament john carroll economic social committee
d002.s008.t002,exclusion,key speaker social conference left right cristina louro employment industrial relations social_affair directorate european commission fernando gome high degree committee region barbara weiler member european parliament josé marium gil-roble vice_president european parliament john carroll economic social committee
d002.s008.t003,conference,key speaker social exclusion left right cristina louro employment industrial relations social_affair directorate european commission fernando gome high degree committee region barbara weiler member european parliament josé marium gil-roble vice_president european parliament john carroll economic social committee
d002.s008.t004,left,key speaker social exclusion conference right cristina louro employment industrial relations social_affair directorate european commission fernando gome high degree committee region barbara weiler member european parliament josé marium gil-roble vice_president european parliament john carroll economic social committee
d002.s008.t005,right,key speaker social exclusion conference left cristina louro employment industrial relations social_affair directorate european commission fernando gome high degree committee region barbara weiler member european parliament josé marium gil-roble vice_president european parliament john carroll economic social committee
d002.s008.t006,employment,key speaker social exclusion conference left right cristina louro industrial relations social_affair directorate european commission fernando gome high degree committee region barbara weiler member european parliament josé marium gil-roble vice_president european parliament john carroll economic social committee
d002.s008.t007,industrial,key speaker social exclusion conference left right cristina louro employment relations social_affair directorate european commission fernando gome high degree committee region barbara weiler member european parliament josé marium gil-roble vice_president european parliament john carroll economic social committee
d002.s008.t008,relations,key speaker social exclusion conference left right cristina louro employment industrial social_affair directorate european commission fernando gome high degree committee region barbara weiler member european parliament josé marium gil-roble vice_president european parliament john carroll economic social committee
d002.s008.t009,social_affair,key speaker social exclusion conference left right cristina louro employment industrial relations directorate european commission fernando gome high degree committee region barbara weiler member european parliament josé marium gil-roble vice_president european parliament john carroll economic social committee
d002.s008.t010,directorate,key speaker social exclusion conference left right cristina louro employment industrial relations social_affair european commission fernando gome high degree committee region barbara weiler member european parliament josé marium gil-roble vice_president european parliament john carroll economic social committee
d002.s008.t011,european,key speaker social exclusion conference left right cristina louro employment industrial relations social_affair directorate commission fernando gome high degree committee region barbara weiler member european parliament josé marium gil-roble vice_president european parliament john carroll economic social committee
d002.s008.t012,commission,key speaker social exclusion conference left right cristina louro employment industrial relations social_affair directorate european fernando gome high degree committee region barbara weiler member european parliament josé marium gil-roble vice_president european parliament john carroll economic social committee
d002.s008.t013,high,key speaker social exclusion conference left right cristina louro employment industrial relations social_affair directorate european commission fernando gome degree committee region barbara weiler member european parliament josé marium gil-roble vice_president european parliament john carroll economic social committee
d002.s008.t014,committee,key speaker social exclusion conference left right cristina louro employment industrial relations social_affair directorate european commission fernando gome high degree region barbara weiler member european parliament josé marium gil-roble vice_president european parliament john carroll economic social committee
d002.s008.t015,member,key speaker social exclusion conference left right cristina louro employment industrial relations social_affair directorate european commission fernando gome high degree committee region barbara weiler european parliament josé marium gil-roble vice_president european parliament john carroll economic social committee
d002.s008.t016,european,key speaker social exclusion conference left right cristina louro employment industrial relations social_affair directorate commission fernando gome high degree committee region barbara weiler member european parliament josé marium gil-roble vice_president european parliament john carroll economic social committee
d002.s008.t017,parliament,key speaker social exclusion conference left right cristina louro employment industrial relations social_affair directorate european commission fernando gome high degree committee region barbara weiler member european josé marium gil-roble vice_president european parliament john carroll economic social committee
d002.s008.t018,vice_president,key speaker social exclusion conference left right cristina louro employment industrial relations social_affair directorate european commission fernando gome high degree committee region barbara weiler member european parliament josé marium gil-roble european parliament john carroll economic social committee
d002.s008.t019,european,key speaker social exclusion conference left right cristina louro employment industrial relations social_affair directorate commission fernando gome high degree committee region barbara weiler member european parliament josé marium gil-roble vice_president european parliament john carroll economic social committee
d002.s008.t020,parliament,key speaker social exclusion conference left right cristina louro employment industrial relations social_affair directorate european commission fernando gome high degree committee region barbara weiler member european josé marium gil-roble vice_president european parliament john carroll economic social committee
d002.s008.t021,economic,key speaker social exclusion conference left right cristina louro employment industrial relations social_affair directorate european commission fernando gome high degree committee region barbara weiler member european parliament josé marium gil-roble vice_president european parliament john carroll social committee
d002.s008.t022,social,key speaker exclusion conference left right cristina louro employment industrial relations social_affair directorate european commission fernando gome high degree committee region barbara weiler member european parliament josé marium gil-roble vice_president european parliament john carroll economic social committee
d002.s008.t023,committee,key speaker social exclusion conference left right cristina louro employment industrial relations social_affair directorate european commission fernando gome high degree region barbara weiler member european parliament josé marium gil-roble vice_president european parliament john carroll economic social committee
d002.s009.t000,case_study,national report contain portfolio initiative best present policy practice improve recruitment training development age worker work place community
d002.s009.t001,national,case_study report contain portfolio initiative best present policy practice improve recruitment training development age worker work place community
d002.s009.t002,report,case_study national contain portfolio initiative best present policy practice improve recruitment training development age worker work place community
d002.s009.t003,contain,case_study national report portfolio initiative best present policy practice improve recruitment training development age worker work place community
d002.s009.t004,portfolio,case_study national report contain initiative best present policy practice improve recruitment training development age worker work place community
d002.s009.t005,initiative,case_study national report contain portfolio best present policy practice improve recruitment training development age worker work place community
d002.s009.t006,present,case_study national report contain portfolio initiative best policy practice improve recruitment training development age worker work place community
d002.s009.t007,policy,case_study national report contain portfolio initiative best present practice improve recruitment training development age worker work place community
d002.s009.t008,practice,case_study national report contain portfolio initiative best present policy improve recruitment training development age worker work place community
d002.s009.t009,improve,case_study national report contain portfolio initiative best present policy practice recruitment training development age worker work place community
d002.s009.t010,recruitment,case_study national report contain portfolio initiative best present policy practice improve training development age worker work place community
d002.s009.t011,training,case_study national report contain portfolio initiative best present policy practice improve recruitment development age worker work place community
d002.s009.t012,development,case_study national report contain portfolio initiative best present policy practice improve recruitment training age worker work place community
d002.s009.t013,age,case_study national report contain portfolio initiative best present policy practice improve recruitment training development worker work place community
d002.s009.t014,worker,case_study national report contain portfolio initiative best present policy practice improve recruitment training development age work place community
d002.s009.t015,work,case_study national report contain portfolio initiative best present policy practice improve recruitment training development age worker place community
d002.s009.t016,place,case_study national report contain portfolio initiative best present policy practice improve recruitment training development age worker work community
d002.s009.t017,community,case_study national report contain portfolio initiative best present policy practice improve recruitment training development age worker work place
d002.s010.t000,country,two three initiative select depth case_study
d002.s010.t001,initiative,country two three select depth case_study
d002.s010.t002,select,country two three initiative depth case_study
d002.s010.t003,further,country two three initiative select depth case_study
d002.s010.t004,depth,country two three initiative select case_study
d002.s010.t005,case_study,country two three initiative select depth
d002.s011.t000,case_study,analyse background initiative impact employment pattern work organisation assess benefit problem initiative
d002.s011.t001,analyse,case_study background initiative impact employment pattern work organisation assess benefit problem initiative
d002.s011.t002,background,case_study analyse initiative impact employment pattern work organisation assess benefit problem initiative
d002.s011.t003,initiative,case_study analyse background impact employment pattern work organisation assess benefit problem initiative
d002.s011.t004,impact,case_study analyse background initiative employment pattern work organisation assess benefit problem initiative
d002.s011.t005,employment,case_study analyse background initiative impact pattern work organisation assess benefit problem initiative
d002.s011.t006,pattern,case_study analyse background initiative impact employment work organisation assess benefit problem initiative
d002.s011.t007,work,case_study analyse background initiative impact employment pattern organisation assess benefit problem initiative
d002.s011.t008,organisation,case_study analyse background initiative impact employment pattern work assess benefit problem initiative
d002.s011.t009,assess,case_study analyse background initiative impact employment pattern work organisation benefit problem initiative
d002.s011.t010,benefit,case_study analyse background initiative impact employment pattern work organisation assess problem initiative
d002.s011.t011,problem,case_study analyse background initiative impact employment pattern work organisation assess benefit initiative
d002.s011.t012,initiative,case_study analyse background impact employment pattern work organisation assess benefit problem initiative
d002.s012.t000,visit,interview key personnel also undertake
d002.s012.t001,interview,visit key personnel also undertake
d002.s012.t002,key,visit interview personnel also undertake
d002.s012.t003,personnel,visit interview key also undertake
d002.s012.t004,also,visit interview key personnel undertake
d002.s012.t005,undertake,visit interview key personnel also
d002.s013.t000,national,study form basis european report synthesise overall practice
d002.s013.t001,study,national form basis european report synthesise overall practice
d002.s013.t002,form,national study basis european report synthesise overall practice
d002.s013.t003,basis,national study form european report synthesise overall practice
d002.s013.t004,european,national study form basis report synthesise overall practice
d002.s013.t005,report,national study form basis european synthesise overall practice
d002.s013.t006,synthesise,national study form basis european report overall practice
d002.s013.t007,overall,national study form basis european report synthesise practice
d002.s013.t008,practice,national study form basis european report synthesise overall
d002.s014.t000,report,casebook initiative publish provide backdrop conference stage autumn
d002.s014.t001,casebook,report initiative publish provide backdrop conference stage autumn
d002.s014.t002,initiative,report casebook publish provide backdrop conference stage autumn
d002.s014.t003,publish,report casebook initiative provide backdrop conference stage autumn
d002.s014.t004,provide,report casebook initiative publish backdrop conference stage autumn
d002.s014.t005,conference,report casebook initiative publish provide backdrop stage autumn
d002.s014.t006,stage,report casebook initiative publish provide backdrop conference autumn
d002.s014.t007,autumn,report casebook initiative publish provide backdrop conference stage
d002.s015.t000,foundation,aim document characteristic age barrier job recruitment training analyse cause
d002.s015.t001,aim,foundation document characteristic age barrier job recruitment training analyse cause
d002.s015.t002,document,foundation aim characteristic age barrier job recruitment training analyse cause
d002.s015.t003,characteristic,foundation aim document age barrier job recruitment training analyse cause
d002.s015.t004,age,foundation aim document characteristic barrier job recruitment training analyse cause
d002.s015.t005,barrier,foundation aim document characteristic age job recruitment training analyse cause
d002.s015.t006,job,foundation aim document characteristic age barrier recruitment training analyse cause
d002.s015.t007,recruitment,foundation aim document characteristic age barrier job training analyse cause
d002.s015.t008,training,foundation aim document characteristic age barrier job recruitment analyse cause
d002.s015.t009,analyse,foundation aim document characteristic age barrier job recruitment training cause
d002.s015.t010,cause,foundation aim document characteristic age barrier job recruitment training analyse
d002.s016.t000,perspective,social partner also examine particular attention pay proposal remove age barrier
d002.s016.t001,social,perspective partner also examine particular attention pay proposal remove age barrier
d002.s016.t002,also,perspective social partner examine particular attention pay proposal remove age barrier
d002.s016.t003,examine,perspective social partner also particular attention pay proposal remove age barrier
d002.s016.t004,particular,perspective social partner also examine attention pay proposal remove age barrier
d002.s016.t005,attention,perspective social partner also examine particular pay proposal remove age barrier
d002.s016.t006,pay,perspective social partner also examine particular attention proposal remove age barrier
d002.s016.t007,proposal,perspective social partner also examine particular attention pay remove age barrier
d002.s016.t008,remove,perspective social partner also examine particular attention pay proposal age barrier
d002.s016.t009,age,perspective social partner also examine particular attention pay proposal remove barrier
d002.s016.t010,barrier,perspective social partner also examine particular attention pay proposal remove age
d002.s017.t000,thirdly,project document assess initiative public private sector combat age barrier especially old worker
d002.s017.t001,project,thirdly document assess initiative public private sector combat age barrier especially old worker
d002.s017.t002,assess,thirdly project document initiative public private sector combat age barrier especially old worker
d002.s017.t003,initiative,thirdly project document assess public private sector combat age barrier especially old worker
d002.s017.t004,public,thirdly project document assess initiative private sector combat age barrier especially old worker
d002.s017.t005,private,thirdly project document assess initiative public sector combat age barrier especially old worker
d002.s017.t006,sector,thirdly project document assess initiative public private combat age barrier especially old worker
d002.s017.t007,age,thirdly project document assess initiative public private sector combat barrier especially old worker
d002.s017.t008,barrier,thirdly project document assess initiative public private sector combat age especially old worker
d002.s017.t009,especially,thirdly project document assess initiative public private sector combat age barrier old worker
d002.s017.t010,old,thirdly project document assess initiative public private sector combat age barrier especially worker
d002.s017.t011,worker,thirdly project document assess initiative public private sector combat age barrier especially old
d002.s018.t000,seek,alternative early retirement redundancy project primarily concern retention reintegrate retrain old worker
d002.s018.t001,alternative,seek early retirement redundancy project primarily concern retention reintegrate retrain old worker
d002.s018.t002,early,seek alternative retirement redundancy project primarily concern retention reintegrate retrain old worker
d002.s018.t003,retirement,seek alternative early redundancy project primarily concern retention reintegrate retrain old worker
d002.s018.t004,redundancy,seek alternative early retirement project primarily concern retention reintegrate retrain old worker
d002.s018.t005,project,seek alternative early retirement redundancy primarily concern retention reintegrate retrain old worker
d002.s018.t006,primarily,seek alternative early retirement redundancy project concern retention reintegrate retrain old worker
d002.s018.t007,concern,seek alternative early retirement redundancy project primarily retention reintegrate retrain old worker
d002.s018.t008,retention,seek alternative early retirement redundancy project primarily concern reintegrate retrain old worker
d002.s018.t009,reintegrate,seek alternative early retirement redundancy project primarily concern retention retrain old worker
d002.s018.t010,retrain,seek alternative early retirement redundancy project primarily concern retention reintegrate old worker
d002.s018.t011,old,seek alternative early retirement redundancy project primarily concern retention reintegrate retrain worker
d002.s018.t012,worker,seek alternative early retirement redundancy project primarily concern retention reintegrate retrain old
d002.s019.t000,gender,ethnic background worker relate age discrimination examine
d002.s019.t001,ethnic,gender background worker relate age discrimination examine
d002.s019.t002,background,gender ethnic worker relate age discrimination examine
d002.s019.t003,worker,gender ethnic background relate age discrimination examine
d002.s019.t004,relate,gender ethnic background worker age discrimination examine
d002.s019.t005,age,gender ethnic background worker relate discrimination examine
d002.s019.t006,discrimination,gender ethnic background worker relate age examine
d002.s019.t007,examine,gender ethnic background worker relate age discrimination
d002.s020.t000,project,also consider initiative combat age discrimination rural_area small medium size enterprise
d002.s020.t001,also,project consider initiative combat age discrimination rural_area small medium size enterprise
d002.s020.t002,consider,project also initiative combat age discrimination rural_area small medium size enterprise
d002.s020.t003,initiative,project also consider combat age discrimination rural_area small medium size enterprise
d002.s020.t004,age,project also consider initiative combat discrimination rural_area small medium size enterprise
d002.s020.t005,discrimination,project also consider initiative combat age rural_area small medium size enterprise
d002.s020.t006,rural_area,project also consider initiative combat age discrimination small medium size enterprise
d002.s020.t007,small,project also consider initiative combat age discrimination rural_area medium size enterprise
d002.s020.t008,enterprise,project also consider initiative combat age discrimination rural_area small medium size
d002.s021.t000,member,seven state cover project belgium france germany greece italy netherland united kingdom
d002.s021.t001,state,seven member cover project belgium france germany greece italy netherland united kingdom
d002.s021.t002,cover,seven member state project belgium france germany greece italy netherland united kingdom
d002.s021.t003,project,seven member state cover belgium france germany greece italy netherland united kingdom
d002.s021.t004,united,seven member state cover project belgium france germany greece italy netherland kingdom
d002.s021.t005,kingdom,seven member state cover project belgium france germany greece italy netherland united
d003.s000.t000,document,summary european public assessment report
d003.s000.t001,summary,document european public assessment report
d003.s000.t002,european,document summary public assessment report
d003.s000.t003,public,document summary european assessment report
d003.s000.t004,assessment,document summary european public report
d003.s000.t005,report,document summary european public assessment
d003.s001.t000,explain,committee medicinal product veterinary use cvmp assess study perform reach recommendation use medicine
d003.s001.t001,committee,explain medicinal product veterinary use cvmp assess study perform reach recommendation use medicine
d003.s001.t002,medicinal,explain committee product veterinary use cvmp assess study perform reach recommendation use medicine
d003.s001.t003,product,explain committee medicinal veterinary use cvmp assess study perform reach recommendation use medicine
d003.s001.t004,veterinary,explain committee medicinal product use cvmp assess study perform reach recommendation use medicine
d003.s001.t005,use,explain committee medicinal product veterinary cvmp assess study perform reach recommendation use medicine
d003.s001.t006,assess,explain committee medicinal product veterinary use cvmp study perform reach recommendation use medicine
d003.s001.t007,study,explain committee medicinal product veterinary use cvmp assess perform reach recommendation use medicine
d003.s001.t008,perform,explain committee medicinal product veterinary use cvmp assess study reach recommendation use medicine
d003.s001.t009,reach,explain committee medicinal product veterinary use cvmp assess study perform recommendation use medicine
d003.s001.t010,recommendation,explain committee medicinal product veterinary use cvmp assess study perform reach use medicine
d003.s001.t011,use,explain committee medicinal product veterinary cvmp assess study perform reach recommendation use medicine
d003.s001.t012,medicine,explain committee medicinal product veterinary use cvmp assess study perform reach recommendation use
d003.s003.t000,contain,cerenia active substance maropitant available tablet solution injection
d003.s003.t001,active,cerenia contain substance maropitant available tablet solution injection
d003.s003.t002,substance,cerenia contain active maropitant available tablet solution injection
d003.s003.t003,available,cerenia contain active substance maropitant tablet solution injection
d003.s003.t004,tablet,cerenia contain active substance maropitant available solution injection
d003.s003.t005,solution,cerenia contain active substance maropitant available tablet injection
d003.s003.t006,injection,cerenia contain active substance maropitant available tablet solution
d003.s004.t000,tablet,pale-orange score line side halve
d003.s004.t001,have,tablet pale-orange score line side halve
d003.s004.t002,score,tablet pale-orange line side halve
d003.s004.t003,line,tablet pale-orange score side halve
d003.s004.t004,side,tablet pale-orange score line halve
d003.s004.t005,so,tablet pale-orange score line side halve
d003.s004.t006,halve,tablet pale-orange score line side
d003.s005.t000,tablet,mark pfizer logo one side letter mpt quantity maropitant side
d003.s005.t001,mark,tablet pfizer logo one side letter mpt quantity maropitant side
d003.s005.t002,logo,tablet mark pfizer one side letter mpt quantity maropitant side
d003.s005.t003,side,tablet mark pfizer logo one letter mpt quantity maropitant side
d003.s005.t004,letter,tablet mark pfizer logo one side mpt quantity maropitant side
d003.s005.t005,quantity,tablet mark pfizer logo one side letter mpt maropitant side
d003.s005.t006,other,tablet mark pfizer logo one side letter mpt quantity maropitant side
d003.s005.t007,side,tablet mark pfizer logo one letter mpt quantity maropitant side
d003.s006.t000,use,cerenia
d003.s007.t000,antiemetic,cerenia mean stop vomit
d003.s007.t001,mean,cerenia antiemetic stop vomit
d003.s007.t002,stop,cerenia antiemetic mean vomit
d003.s007.t003,vomit,cerenia antiemetic mean stop
d003.s008.t000,use,dog prevent vomit vomit cause chemotherapy medicine use treatment cancer know cause vomit
d003.s008.t001,dog,use prevent vomit vomit cause chemotherapy medicine use treatment cancer know cause vomit
d003.s008.t002,prevent,use dog vomit vomit cause chemotherapy medicine use treatment cancer know cause vomit
d003.s008.t003,vomit,use dog prevent vomit cause chemotherapy medicine use treatment cancer know cause vomit
d003.s008.t004,vomit,use dog prevent vomit cause chemotherapy medicine use treatment cancer know cause vomit
d003.s008.t005,cause,use dog prevent vomit vomit chemotherapy medicine use treatment cancer know cause vomit
d003.s008.t006,chemotherapy,use dog prevent vomit vomit cause medicine use treatment cancer know cause vomit
d003.s008.t007,medicine,use dog prevent vomit vomit cause chemotherapy use treatment cancer know cause vomit
d003.s008.t008,use,dog prevent vomit vomit cause chemotherapy medicine use treatment cancer know cause vomit
d003.s008.t009,treatment,use dog prevent vomit vomit cause chemotherapy medicine use cancer know cause vomit
d003.s008.t010,cancer,use dog prevent vomit vomit cause chemotherapy medicine use treatment know cause vomit
d003.s008.t011,know,use dog prevent vomit vomit cause chemotherapy medicine use treatment cancer cause vomit
d003.s008.t012,cause,use dog prevent vomit vomit chemotherapy medicine use treatment cancer know cause vomit
d003.s008.t013,vomit,use dog prevent vomit cause chemotherapy medicine use treatment cancer know cause vomit
d003.s009.t000,combination,supportive measure veterinary treatment special diet cerenia also use treatment vomiting either injection injection follow tablet
d003.s009.t001,supportive,combination measure veterinary treatment special diet cerenia also use treatment vomiting either injection injection follow tablet
d003.s009.t002,measure,combination supportive veterinary treatment special diet cerenia also use treatment vomiting either injection injection follow tablet
d003.s009.t003,other,combination supportive measure veterinary treatment special diet cerenia also use treatment vomiting either injection injection follow tablet
d003.s009.t004,veterinary,combination supportive measure treatment special diet cerenia also use treatment vomiting either injection injection follow tablet
d003.s009.t005,treatment,combination supportive measure veterinary special diet cerenia also use treatment vomiting either injection injection follow tablet
d003.s009.t006,special,combination supportive measure veterinary treatment diet cerenia also use treatment vomiting either injection injection follow tablet
d003.s009.t007,diet,combination supportive measure veterinary treatment special cerenia also use treatment vomiting either injection injection follow tablet
d003.s009.t008,also,combination supportive measure veterinary treatment special diet cerenia use treatment vomiting either injection injection follow tablet
d003.s009.t009,use,combination supportive measure veterinary treatment special diet cerenia also treatment vomiting either injection injection follow tablet
d003.s009.t010,treatment,combination supportive measure veterinary special diet cerenia also use treatment vomiting either injection injection follow tablet
d003.s009.t011,vomiting,combination supportive measure veterinary treatment special diet cerenia also use treatment either injection injection follow tablet
d003.s009.t012,injection,combination supportive measure veterinary treatment special diet cerenia also use treatment vomiting either injection follow tablet
d003.s009.t013,injection,combination supportive measure veterinary treatment special diet cerenia also use treatment vomiting either injection follow tablet
d003.s009.t014,follow,combination supportive measure veterinary treatment special diet cerenia also use treatment vomiting either injection injection tablet
d003.s009.t015,tablet,combination supportive measure veterinary treatment special diet cerenia also use treatment vomiting either injection injection follow
d003.s010.t000,purpose,cerenia give five day
d003.s010.t001,give,purpose cerenia five day
d003.s010.t002,day,purpose cerenia give five
d003.s012.t000,block,cerenia neurokinin nk1 receptor act central_nervous_system
d003.s012.t001,receptor,cerenia block neurokinin nk1 act central_nervous_system
d003.s012.t002,act,cerenia block neurokinin nk1 receptor central_nervous_system
d003.s012.t003,central_nervous_system,cerenia block neurokinin nk1 receptor act
d003.s013.t000,study,cerenia
d003.s014.t000,large_number,study cerenia carry_out either laboratory dog animal patient veterinary practise several european_country usa
d003.s014.t001,study,large_number cerenia carry_out either laboratory dog animal patient veterinary practise several european_country usa
d003.s014.t002,carry_out,large_number study cerenia either laboratory dog animal patient veterinary practise several european_country usa
d003.s014.t003,laboratory,large_number study cerenia carry_out either dog animal patient veterinary practise several european_country usa
d003.s014.t004,dog,large_number study cerenia carry_out either laboratory animal patient veterinary practise several european_country usa
d003.s014.t005,patient,large_number study cerenia carry_out either laboratory dog animal veterinary practise several european_country usa
d003.s014.t006,veterinary,large_number study cerenia carry_out either laboratory dog animal patient practise several european_country usa
d003.s014.t007,several,large_number study cerenia carry_out either laboratory dog animal patient veterinary practise european_country usa
d003.s014.t008,european_country,large_number study cerenia carry_out either laboratory dog animal patient veterinary practise several usa
d003.s015.t000,benefit,cerenia show study
d003.s015.t001,show,benefit cerenia study
d003.s015.t002,study,benefit cerenia show
d003.s016.t000,result,study show cerenia effective placebo less vomiting see dog receive medicine dog receive placebo treatment prevention vomiting
d003.s016.t001,study,result show cerenia effective placebo less vomiting see dog receive medicine dog receive placebo treatment prevention vomiting
d003.s016.t002,show,result study cerenia effective placebo less vomiting see dog receive medicine dog receive placebo treatment prevention vomiting
d003.s016.t003,more,result study show cerenia effective placebo less vomiting see dog receive medicine dog receive placebo treatment prevention vomiting
d003.s016.t004,effective,result study show cerenia placebo less vomiting see dog receive medicine dog receive placebo treatment prevention vomiting
d003.s016.t005,placebo,result study show cerenia effective less vomiting see dog receive medicine dog receive placebo treatment prevention vomiting
d003.s016.t006,less,result study show cerenia effective placebo vomiting see dog receive medicine dog receive placebo treatment prevention vomiting
d003.s016.t007,vomiting,result study show cerenia effective placebo less see dog receive medicine dog receive placebo treatment prevention vomiting
d003.s016.t008,see,result study show cerenia effective placebo less vomiting dog receive medicine dog receive placebo treatment prevention vomiting
d003.s016.t009,dog,result study show cerenia effective placebo less vomiting see receive medicine dog receive placebo treatment prevention vomiting
d003.s016.t010,receive,result study show cerenia effective placebo less vomiting see dog medicine dog receive placebo treatment prevention vomiting
d003.s016.t011,medicine,result study show cerenia effective placebo less vomiting see dog receive dog receive placebo treatment prevention vomiting
d003.s016.t012,dog,result study show cerenia effective placebo less vomiting see receive medicine dog receive placebo treatment prevention vomiting
d003.s016.t013,receive,result study show cerenia effective placebo less vomiting see dog medicine dog receive placebo treatment prevention vomiting
d003.s016.t014,placebo,result study show cerenia effective less vomiting see dog receive medicine dog receive placebo treatment prevention vomiting
d003.s016.t015,treatment,result study show cerenia effective placebo less vomiting see dog receive medicine dog receive placebo prevention vomiting
d003.s016.t016,prevention,result study show cerenia effective placebo less vomiting see dog receive medicine dog receive placebo treatment vomiting
d003.s016.t017,vomiting,result study show cerenia effective placebo less see dog receive medicine dog receive placebo treatment prevention vomiting
d003.s017.t000,treatment,vomiting dog start injection since vomiting animal might able keep tablet might throw intact tablet
d003.s017.t001,vomiting,treatment dog start injection since vomiting animal might able keep tablet might throw intact tablet
d003.s017.t002,dog,treatment vomiting start injection since vomiting animal might able keep tablet might throw intact tablet
d003.s017.t003,start,treatment vomiting dog injection since vomiting animal might able keep tablet might throw intact tablet
d003.s017.t004,injection,treatment vomiting dog start since vomiting animal might able keep tablet might throw intact tablet
d003.s017.t005,vomiting,treatment dog start injection since vomiting animal might able keep tablet might throw intact tablet
d003.s017.t006,animal,treatment vomiting dog start injection since vomiting might able keep tablet might throw intact tablet
d003.s017.t007,not,treatment vomiting dog start injection since vomiting animal might able keep tablet might throw intact tablet
d003.s017.t008,able,treatment vomiting dog start injection since vomiting animal might keep tablet might throw intact tablet
d003.s017.t009,tablet,treatment vomiting dog start injection since vomiting animal might able keep might throw intact tablet
d003.s017.t010,intact,treatment vomiting dog start injection since vomiting animal might able keep tablet might throw tablet
d003.s017.t011,tablet,treatment vomiting dog start injection since vomiting animal might able keep might throw intact tablet
d003.s017.t012,again,treatment vomiting dog start injection since vomiting animal might able keep tablet might throw intact tablet
d003.s018.t000,follow-up,treatment animal owner administer tablet dog
d003.s018.t001,treatment,follow-up animal owner administer tablet dog
d003.s018.t002,owner,follow-up treatment animal administer tablet dog
d003.s018.t003,administer,follow-up treatment animal owner tablet dog
d003.s018.t004,tablet,follow-up treatment animal owner administer dog
d003.s018.t005,dog,follow-up treatment animal owner administer tablet
d003.s019.t000,also,treatment vomiting together_with supportive measure veterinary therapy address underlie cause vomiting
d003.s019.t001,treatment,also vomiting together_with supportive measure veterinary therapy address underlie cause vomiting
d003.s019.t002,vomiting,also treatment together_with supportive measure veterinary therapy address underlie cause vomiting
d003.s019.t003,only,also treatment vomiting together_with supportive measure veterinary therapy address underlie cause vomiting
d003.s019.t004,together_with,also treatment vomiting supportive measure veterinary therapy address underlie cause vomiting
d003.s019.t005,other,also treatment vomiting together_with supportive measure veterinary therapy address underlie cause vomiting
d003.s019.t006,supportive,also treatment vomiting together_with measure veterinary therapy address underlie cause vomiting
d003.s019.t007,measure,also treatment vomiting together_with supportive veterinary therapy address underlie cause vomiting
d003.s019.t008,other,also treatment vomiting together_with supportive measure veterinary therapy address underlie cause vomiting
d003.s019.t009,veterinary,also treatment vomiting together_with supportive measure therapy address underlie cause vomiting
d003.s019.t010,therapy,also treatment vomiting together_with supportive measure veterinary address underlie cause vomiting
d003.s019.t011,address,also treatment vomiting together_with supportive measure veterinary therapy underlie cause vomiting
d003.s019.t012,underlie,also treatment vomiting together_with supportive measure veterinary therapy address cause vomiting
d003.s019.t013,cause,also treatment vomiting together_with supportive measure veterinary therapy address underlie vomiting
d003.s019.t014,vomiting,also treatment together_with supportive measure veterinary therapy address underlie cause vomiting
d003.s020.t000,risk,associate cerenia
d003.s020.t001,associate,risk cerenia
d003.s021.t000,generally,cerenia well tolerate administer daily dosage time recommend dose extended period_of_time time recommend maximum duration treatment
d003.s021.t001,well,cerenia generally tolerate administer daily dosage time recommend dose extended period_of_time time recommend maximum duration treatment
d003.s021.t002,tolerate,cerenia generally well administer daily dosage time recommend dose extended period_of_time time recommend maximum duration treatment
d003.s021.t003,administer,cerenia generally well tolerate daily dosage time recommend dose extended period_of_time time recommend maximum duration treatment
d003.s021.t004,daily,cerenia generally well tolerate administer dosage time recommend dose extended period_of_time time recommend maximum duration treatment
d003.s021.t005,dosage,cerenia generally well tolerate administer daily time recommend dose extended period_of_time time recommend maximum duration treatment
d003.s021.t006,time,cerenia generally well tolerate administer daily dosage recommend dose extended period_of_time time recommend maximum duration treatment
d003.s021.t007,recommend,cerenia generally well tolerate administer daily dosage time dose extended period_of_time time recommend maximum duration treatment
d003.s021.t008,dose,cerenia generally well tolerate administer daily dosage time recommend extended period_of_time time recommend maximum duration treatment
d003.s021.t009,extended,cerenia generally well tolerate administer daily dosage time recommend dose period_of_time time recommend maximum duration treatment
d003.s021.t010,period_of_time,cerenia generally well tolerate administer daily dosage time recommend dose extended time recommend maximum duration treatment
d003.s021.t011,time,cerenia generally well tolerate administer daily dosage recommend dose extended period_of_time time recommend maximum duration treatment
d003.s021.t012,maximum,cerenia generally well tolerate administer daily dosage time recommend dose extended period_of_time time recommend duration treatment
d003.s021.t013,duration,cerenia generally well tolerate administer daily dosage time recommend dose extended period_of_time time recommend maximum treatment
d003.s021.t014,treatment,cerenia generally well tolerate administer daily dosage time recommend dose extended period_of_time time recommend maximum duration
d003.s022.t000,precaution,person give medicine come_into contact animal
d003.s022.t001,person,precaution give medicine come_into contact animal
d003.s022.t002,give,precaution person medicine come_into contact animal
d003.s022.t003,medicine,precaution person give come_into contact animal
d003.s022.t004,come_into,precaution person give medicine contact animal
d003.s022.t005,contact,precaution person give medicine come_into animal
d003.s022.t006,animal,precaution person give medicine come_into contact
d003.s023.t000,not,cerenia represent particular risk people
d003.s023.t001,represent,cerenia particular risk people
d003.s023.t002,particular,cerenia represent risk people
d003.s023.t003,risk,cerenia represent particular people
d003.s023.t004,people,cerenia represent particular risk
